NCT04804059View on ClinicalTrials.gov

A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 17, 2018

Primary Completion Date

September 26, 2018

Study Completion Date

September 26, 2018

Conditions
Fungal Infection
Interventions
DRUG

[14C]-APX001 Oral Solution

Total dose containing NMT 3.1 MBq (84.0 µCi) 14C

DRUG

[14C]-APX001 Solution for Infusion

Total dose containing NMT 3.4 MBq (93.0 µCi) 14C

Trial Locations (1)

NG11 6JS

Quotient Sciences, Ruddington

Sponsors
All Listed Sponsors
lead

Basilea Pharmaceutica

INDUSTRY

NCT04804059 - A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males | Biotech Hunter | Biotech Hunter